Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 5
1989 7
1990 7
1991 7
1992 11
1993 6
1994 6
1995 3
1996 4
1997 8
1998 5
1999 15
2000 15
2001 27
2002 35
2003 34
2004 26
2005 33
2006 51
2007 60
2008 65
2009 74
2010 67
2011 62
2012 63
2013 79
2014 79
2015 61
2016 60
2017 52
2018 38
2019 37
2020 48
2021 53
2022 46
2023 37
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

1,202 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Flather MD, et al. Eur Heart J. 2005 Feb;26(3):215-25. doi: 10.1093/eurheartj/ehi115. Epub 2005 Jan 9. Eur Heart J. 2005. PMID: 15642700 Clinical Trial.
The SENIORS study was performed to assess effects of the beta-blocker, nebivolol, in patients >/=70 years, regardless of ejection fraction. ...There was no significant influence of age, gender, or ejection fraction on the effect of nebivolol on the primary outcom …
The SENIORS study was performed to assess effects of the beta-blocker, nebivolol, in patients >/=70 years, regardless of ejection …
Therapeutic Properties of Highly Selective beta-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
AlHabeeb W, Mrabeti S, Abdelsalam AAI. AlHabeeb W, et al. Cardiovasc Drugs Ther. 2022 Oct;36(5):959-971. doi: 10.1007/s10557-021-07205-y. Epub 2021 Jun 9. Cardiovasc Drugs Ther. 2022. PMID: 34106365 Free PMC article. Review.
Nebivolol has additional vasodilator actions, related to enhanced release of NO in the vascular wall. In principle, this additional mechanism compared with bisoprolol might lead to more potent vasodilatation, which in turn might influence the effectiveness of nebivolol
Nebivolol has additional vasodilator actions, related to enhanced release of NO in the vascular wall. In principle, this additional m
Clinical pharmacokinetics of nebivolol: a systematic review.
Hanif N, Zamir A, Imran I, Saeed H, Majeed A, Rehman AU, Ashraf W, Alqahtani F, Rasool MF. Hanif N, et al. Drug Metab Rev. 2023 Nov;55(4):428-440. doi: 10.1080/03602532.2023.2271195. Epub 2023 Oct 28. Drug Metab Rev. 2023. PMID: 37849071 Review.
Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile dysfunction, vascular disease, and diabetes mellitus. ...The area under the concentration-time curve from zero to infinity (AUC(0-)) was 15 times greater in poor metabolizers (PMs) t
Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile dysfunction, vascular disease, and diabete
Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension.
Paton DM. Paton DM. Drugs Today (Barc). 2017 Jan;53(1):19-26. doi: 10.1358/dot.2017.53.1.2560078. Drugs Today (Barc). 2017. PMID: 28387384 Review.
Clinical trials demonstrated that a fixed-dose combination (FDC) of the beta-blocker nebivolol (5 mg) and the angiotensin II antagonist valsartan (80 mg) produced a significant reduction of both diastolic and systolic blood pressure in patients with hypertension. Both n
Clinical trials demonstrated that a fixed-dose combination (FDC) of the beta-blocker nebivolol (5 mg) and the angiotensin II antagoni …
Nebivolol in the treatment of arterial hypertension.
Olawi N, Krüger M, Grimm D, Infanger M, Wehland M. Olawi N, et al. Basic Clin Pharmacol Toxicol. 2019 Sep;125(3):189-201. doi: 10.1111/bcpt.13248. Epub 2019 Jul 4. Basic Clin Pharmacol Toxicol. 2019. PMID: 31066991 Free article. Review.
This MiniReview reports the current knowledge about the treatment of arterial hypertension with the third-generation beta-adrenoceptor antagonist (BAA) nebivolol. Furthermore, it reviews the advantages of nebivolol compared to the earlier generation of BAAs with res …
This MiniReview reports the current knowledge about the treatment of arterial hypertension with the third-generation beta-adrenoceptor antag …
Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet.
Battise D, Boland CL, Nuzum DS. Battise D, et al. Ann Pharmacother. 2019 Apr;53(4):402-412. doi: 10.1177/1060028018813575. Epub 2018 Nov 18. Ann Pharmacother. 2019. PMID: 30449127 Review.
Substudy analyses confirmed this among subgroups and demonstrated that nebivolol/valsartan decreased plasma renin and aldosterone levels. ...CONCLUSION: Nebivolol/valsartan combination may offer a benefit to patients with an indication for both classes who desire to …
Substudy analyses confirmed this among subgroups and demonstrated that nebivolol/valsartan decreased plasma renin and aldosterone lev …
Combination cardiovascular drugs.
Dalal KS, Bridgeman MB. Dalal KS, et al. Nursing. 2017 Aug;47(8):70. doi: 10.1097/01.NURSE.0000521021.69520.76. Nursing. 2017. PMID: 28746107 No abstract available.
A Review of Nebivolol Pharmacology and Clinical Evidence.
Fongemie J, Felix-Getzik E. Fongemie J, et al. Drugs. 2015 Aug;75(12):1349-71. doi: 10.1007/s40265-015-0435-5. Drugs. 2015. PMID: 26177892 Free PMC article. Review.
Nebivolol is a highly selective beta1-adrenergic receptor antagonist with a pharmacologic profile that differs from those of other drugs in its class. ...Nebivolol also has beneficial effects on central blood pressure compared with other beta-blockers. ...
Nebivolol is a highly selective beta1-adrenergic receptor antagonist with a pharmacologic profile that differs from those of other dr
Nebivolol: endothelium-mediated vasodilating effect.
Ritter JM. Ritter JM. J Cardiovasc Pharmacol. 2001 Dec;38 Suppl 3:S13-6. doi: 10.1097/00005344-200112003-00003. J Cardiovasc Pharmacol. 2001. PMID: 11811387 Review.
Nebivolol and atenolol have been compared in phenylephrine preconstricted dorsal hand veins of 11 healthy men. ...LNMMA inhibited responses to nebivolol and carbachol to a significantly greater extent than it reduced responses to nitroprusside. ...
Nebivolol and atenolol have been compared in phenylephrine preconstricted dorsal hand veins of 11 healthy men. ...LNMMA inhibited res
Nebivolol: a review.
Cockcroft J. Cockcroft J. Expert Opin Pharmacother. 2004 Apr;5(4):893-9. doi: 10.1517/14656566.5.4.893. Expert Opin Pharmacother. 2004. PMID: 15102571 Review.
Nebivolol is a vasodilating beta-blocker, which can be distinguished from other beta-blockers by its haemodynamic profile. ...The effects of nebivolol have been compared with other beta-blockers and also with other classes of antihypertensive agents. ...
Nebivolol is a vasodilating beta-blocker, which can be distinguished from other beta-blockers by its haemodynamic profile. ...The eff
1,202 results